Ireland· IE-PA-EU/1/15/1064/002
Imlygic 10e8 plaque forming units (PFU)/mL solution for injection
A blinatumomab product containing talimogene laherparepvec, registered in Ireland by Amgen Europe B.V..
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Talimogene laherparepvec
- Manufacturer
- Amgen Europe B.V.
- Country
- Ireland (IE)
- ATC code
- L01XC19
- ATC class
- Blinatumomab
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/15/1064/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
139 interactions on record for blinatumomab.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Blinatumomab · interactions on record
139 records
- 37 severe
- 102 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Blinatumomab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomImlygic 100million plaque forming units/1ml solution for injection vialsAmgen Ltd
- SwitzerlandImlygic
- CzechiaIMLYGICAmgen Europe B.V., Breda
- SpainIMLYGIC 1x10e6 UFP/ml solucion inyectableAmgen Europe B.V.
- FinlandImlygicAmgen Europe B.V.
- BelgiumImlygic 1 10*6 PFU/mlAmgen Europe
- United StatesImlygicAmgen Inc
- IcelandImlygicAmgen Europe B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Imlygic
- Norway · Imlygic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e3f6e989-b26a-4316-93e2-27c673c2bab6 GET /v1/drugs/e3f6e989-b26a-4316-93e2-27c673c2bab6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Intralesional use"
],
"source": "hpra",
"atc_all": [
"L01XC",
"L01XC19"
],
"strength": null,
"pa_number": "EU/1/15/1064/002",
"substances": [
"Talimogene laherparepvec"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about blinatumomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.